Clinical trials: Clinical
Neoplasms, NUT Carcinoma
BI 894999 First in Human Dose Finding Study in Advanced Malignancies
This study is open to adults with different types of advanced cancer (solid tumours). The study is also open to patients with diffuse large B-cell lymphoma in whom previous treatment was not successful.
- Trial name
- NCT02516553
- Testing
- BI 894999
- Where
- 16 sites in United States, Belgium and 4 more
- Volunteers
- 174 people
- Sponsor
- Boehringer Ingelheim
Open Abdomen
Post Market Clinical Follow Up Study of Avance Foam Abdominal Dressing Kit in Open Abdomen
The investigation is a Post Marketing Follow-Up Study for the Avance Foam Abdominal Dressing Kit conducted as part of Mölnlycke Health Care's quality system.
- Trial name
- NCT01968811
- Testing
- Avance Foam dressing kit
- Where
- Sweden
- Volunteers
- 10 people
- Sponsor
- Molnlycke Health Care AB
Pulmonary Arterial Hypertension
Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso
This was a Phase 1b safety and tolerability single-sequence study in which PAH subjects on a stable regimen of Tyvaso switched to a corresponding dose of TreT.
- Trial name
- BREEZE (NCT03950739)
- Testing
- Treprostinil Inhalation Powder
- Where
- 16 sites in United States
- Volunteers
- 51 people
- Sponsor
- United Therapeutics
Acne Vulgaris
A Efficacy and Safety of Duac™Compared With Clindamycin Phosphate Gel in the Treatment of Mild to Moderate Acne Vulgaris
This is a multicentre, randomized, assessor-blind, comparator-controlled evaluation of the efficacy, safety, and tolerability of Duac™Once Daily Gel and clindamycin phosphate gel in the topical treatment of mild to moderate…
- Trial name
- NCT01915732
- Testing
- Duac™Once Daily Gel, 1% clindamycin phosphate gel
- Where
- 24 sites in China
- Volunteers
- 1,018 people
- Sponsor
- GlaxoSmithKline
Papulopustular Rosacea
Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea
Rosacea is a common chronic inflammatory relapsing-remitting skin condition almost exclusively affecting the central area of the face and the eyes.
- Trial name
- NCT05150587
- Testing
- Rifaximin
- Where
- 38 sites in United States
- Volunteers
- 216 people
- Sponsor
- Alfasigma S.p.A.
Advanced, Androgen Receptor Positive Triple Negative Breast Cancer
Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer
The purpose of this study is to determine if enzalutamide is safe and effective in the treatment of patients with advanced breast cancer that express the androgen receptor but do not express the estrogen or progesterone receptor…
- Trial name
- NCT01889238
- Testing
- Enzalutamide
- Where
- 132 sites in United States, Belgium and 5 more
- Volunteers
- 118 people
- Sponsor
- Pfizer
Full Thickness Rotator Cuff Tear
BioFiber Scaffold Post-Market Observational Study
The aim of this study is to collect and report data from a consecutive series of patients implanted with these products as part of a post-market surveillance plan for CE Mark approval in the European Union.
- Trial name
- NCT01849458
- Testing
- BioFiber
- Where
- 3 sites in United States, France
- Volunteers
- 50 people
- Sponsor
- Stryker Trauma and Extremities
Heart Transplant
Donors After Circulatory Death Heart Trial
To evaluate the effectiveness of the OCS Heart System to resuscitate, preserve and assess hearts donated after circulatory death for transplantation to increase the pool of donor hearts available for transplantation.
- Trial name
- NCT03831048
- Testing
- OCS Heart System, Cold Storage
- Where
- 25 sites in United States
- Volunteers
- 180 people
- Sponsor
- TransMedics
Mycobacterium Infections, Nontuberculous
Pilot Trial of Inhaled Molgramostim in Non-tuberculous Mycobacterial (NTM) Infection
The trial is an open-label, non-controlled, multicenter, pilot clinical trial of inhaled molgramostim (recombinant human granulocyte-macrophage colony stimulating factor; rhGM-CSF) in subjects with persistent pulmonary…
- Trial name
- OPTIMA (NCT03421743)
- Testing
- Inhaled molgramostim, Antimycobacterial regimen
- Where
- 5 sites in Australia, United Kingdom
- Volunteers
- 32 people
- Sponsor
- Savara Inc.
Multiple Sclerosis
REbif FLEXible Dosing in Early Multiple Sclerosis (MS)
The study is a 24 months randomized, double-blind, Placebo-controlled, multi-center clinical trial with an optional 12 months open label extension.
- Trial name
- REFLEX (NCT00404352)
- Testing
- RNF
- Where
- 67 sites in Argentina, Australia and 25 more
- Volunteers
- 517 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Visual Acuity
Clinical Evaluation of an Investigational Lipid Drop in Non-contact Lens Wearing Patients
This is a double-masked, randomized, bilateral, 2-Arm parallel group study. Subjects are scheduled for 3 study visits (screening/baseline, 7-Day and 30-Day follow-up visits) over a period of one month.
- Trial name
- NCT03995355
- Testing
- 9618X investigational lipid eye drops, Blink® Tears
- Where
- United States
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Vision Care, Inc.
Heart Failure
Attain Success Clinical Trial
The purpose of the study is to assess lead implant success and complication rate using the Medtronic Attain Family of left-heart leads and delivery catheters.
- Trial name
- NCT00990964
- Testing
- Attain Success Lead
- Where
- 108 sites in United States, Canada and 14 more
- Volunteers
- 2,014 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Myopia, Astigmatism
Clinical Evaluation of Two Monthly Replacement Silicone Hydrogel Contact Lenses
The purpose of this study is to evaluate differences in the comfort at the end of the month between Air Optix® lenses versus Biofinity® lenses in habitual daily wear symptomatic soft contact lens wearers.
- Trial name
- NCT01629693
- Testing
- Lotrafilcon B contact lenses, Comfilcon A contact lenses
- Volunteers
- 398 people
- Sponsor
- Alcon Research
Septic Shock
Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial
This is a double-blind, randomised, placebo-controlled, two-part adaptive clinical trial. The trial is designed to investigate the efficacy and safety of multiple dosing regimens of selepressin and to confirm the efficacy and…
- Trial name
- SEPSIS-ACT (NCT02508649)
- Testing
- selepressin
- Where
- 21 sites in United States, Belgium and 3 more
- Volunteers
- 868 people
- Sponsor
- Ferring Pharmaceuticals
Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.
- Trial name
- KRYSTAL-12 (NCT04685135)
- Testing
- MRTX849, Docetaxel
- Where
- 380 sites in United States, Australia and 22 more
- Volunteers
- 453 people
- Sponsor
- Mirati Therapeutics Inc.
Ametropia
Clinical Characterization of Symptomatic Populations
This is an unmasked, non-randomized, single arm, stratified, dispensing investigation of symptomatic and asymptomatic subject populations.
- Trial name
- NCT03319212
- Testing
- senofilcon A contact lenses
- Where
- 2 sites in United States, Canada
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Vision Care, Inc.
Platinum-resistant Ovarian Cancer
Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian
Afuresertib is an AKT inhibitor, a new class of agents under development that may provide physicians with a new clinical option to control platinum resistant ovarian cancer (PROC) progression.
- Trial name
- PROFECTA-II (NCT04374630)
- Testing
- Paclitaxel, Afuresertib
- Where
- 47 sites in United States, China
- Volunteers
- 150 people
- Sponsor
- Laekna Limited
Moderate to Severe Psoriasis
Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy
Adalimumab has recently been authorized for active psoriasis in Peru and local experience is very low. The aim of this study is to obtain Peruvian data of clinical effectiveness and impact on health-related quality of life with…
- Trial name
- NCT01156532
- Where
- 3 sites in Peru
- Volunteers
- 30 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Visual Acuity
Clinical Evaluation of Approved Contact Lenses
This is a 4-week, randomized, double-masked study where subjects will wear bilaterally test and control lenses in random succession. The objective is to evaluate materials from different suppliers.
- Trial name
- NCT02699593
- Testing
- Test Contact Lens, Control Contact Lens
- Where
- 7 sites in United States
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Vision Care, Inc.
Presbyopia
CLEAR CARE® PLUS for Presbyopic Contact Lens Wearers
The purpose of this study is to evaluate CLEAR CARE® PLUS (CCP) compared to non-HYDRAGLYDE® multi-purpose contact lens solutions in presbyopes currently wearing soft contact lenses and experiencing symptoms of dryness.
- Trial name
- NCT02965833
- Testing
- 3% hydrogen peroxide solution with HydraGlyde® Moisture Matrix, Habitual Multi-Purpose Contact Lens Solution, Habitual Contact Lenses
- Volunteers
- 126 people
- Sponsor
- Alcon, a Novartis Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.